- Home
- CHI vs OPT Comparison
CHI vs OPT Comparison
Compare CHI & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- OPT
- Stock Information
- Founded
- CHI 2002
- OPT 1984
- Country
- CHI United States
- OPT Australia
- Employees
- CHI N/A
- OPT N/A
- Industry
- CHI Investment Managers
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHI Finance
- OPT Health Care
- Exchange
- CHI Nasdaq
- OPT Nasdaq
- Market Cap
- CHI 910.4M
- OPT 767.9M
- IPO Year
- CHI N/A
- OPT 2020
- Fundamental
- Price
- CHI $12.00
- OPT $3.34
- Analyst Decision
- CHI
- OPT Strong Buy
- Analyst Count
- CHI 0
- OPT 1
- Target Price
- CHI N/A
- OPT $12.00
- AVG Volume (30 Days)
- CHI 186.2K
- OPT 12.3K
- Earning Date
- CHI 01-01-0001
- OPT 08-30-2024
- Dividend Yield
- CHI 9.90%
- OPT N/A
- EPS Growth
- CHI N/A
- OPT N/A
- EPS
- CHI N/A
- OPT N/A
- Revenue
- CHI N/A
- OPT $261,859.00
- Revenue This Year
- CHI N/A
- OPT N/A
- Revenue Next Year
- CHI N/A
- OPT $46,864.64
- P/E Ratio
- CHI N/A
- OPT N/A
- Revenue Growth
- CHI N/A
- OPT N/A
- 52 Week Low
- CHI $9.70
- OPT $1.79
- 52 Week High
- CHI $11.61
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- CHI 51.53
- OPT 43.16
- Support Level
- CHI $11.70
- OPT $3.15
- Resistance Level
- CHI $12.19
- OPT $3.39
- Average True Range (ATR)
- CHI 0.19
- OPT 0.18
- MACD
- CHI -0.04
- OPT -0.00
- Stochastic Oscillator
- CHI 47.62
- OPT 27.49
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.